KFAS
CRL icon

Keating Financial Advisory Services’s Charles River Laboratories CRL Stock Holding History

Keating Financial Advisory Services’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.9K Buy
26
+5
+24% +$890 ﹤0.01% 1467
2026
Q1 		$3.62K Sell
21
-4
-16% -$742 ﹤0.01% 1593
2025
Q4 		$4.99K Buy
+25
New +$4.54K ﹤0.01% 1281

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Keating Financial Advisory Services's CRL Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Charles River Laboratories (CRL) stake by 24% in Q2 2026, buying an estimated $890 and bringing the position to 26 shares worth $5.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1467.

Keating Financial Advisory Services first reported a position in CRL in Q4 2025 and has held it in 3 quarters since. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Keating Financial Advisory Services held 26 shares of Charles River Laboratories worth $5.9K as of Q2 2026.
  • Keating Financial Advisory Services bought 5 Charles River Laboratories shares in Q2 2026, an estimated $890.
  • Charles River Laboratories made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1467 holding.
  • Keating Financial Advisory Services first reported a position in Charles River Laboratories in Q4 2025 and has held it in 3 quarters since.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.